Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term tobramycin inhalation in bronchiectasis with Pseudomonas aeruginosa infection
ChiCTR2500105355Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tobramycin in bronchiectasis and Pseudomonal infection, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoints: ELF-to-serum penetration ratio of tobramycin at steady state, Change in Pseudomonas aeruginosa bacterial load in ELF and 5 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tobramycin
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on ChiCTR2500105355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105355.